# A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

> **NCT05900765** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 54 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Zimberelimab 240mg

## Key facts

- **NCT ID:** NCT05900765
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900765, "A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05900765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*